Please ensure Javascript is enabled for purposes of website accessibility

Why Alexion Pharmacteuicals Sank 8.9% in November

By Brian Feroldi - Dec 5, 2017 at 1:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A handful of positive updates still wasn't enough to reverse the negative sentiment.

What happened

Shares of Alexion Pharmaceuticals (ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't appear to be any company-specific news that can explain the decline. Instead, it's likely that the pessimism from October simply carried over.

Business woman looking worried at computer

Image source: Getty Images.

So what

While it was mostly a quiet month for the biotech, a few key news items were released during the period:

  • Alexion announced that it would be presenting new data related to ALXN1210 -- a long-acting treatment for paroxysmal nocturnal hemoglobinuria -- at the upcoming American Society of Hematology in December.
  • The company released interim data showing that 80% of patients with rapidly progressive lysosomal acid lipase deficiency who used Kanuma survived beyond 1 year of age. That represents a vast improvement when compared to previous treatment options.
  • Alexion announced that it was issued a new patent for Soliris in Japan. This should extend the drug's patent protection into 2027.

However, this news simply wasn't good enough to appease traders. 

Now what

It hasn't been a fun couple of years to be a shareholder of Alexion. Between management turnover and looming competitive threats, bulls haven't been given many reasons to celebrate.

You could argue that the pessimism has turned Alexion into a value stock today. After all, the company's profits are expected to grow by double digits over the next five years. That's attractive for a company that's only trading around 16 times next year's earnings estimates.

On the flip side, Soliris is still the company's cash cow and it remains one of the most expensive drugs in the world. If the U.S. gets serious about cracking down on runaway drug prices, Alexion's financial statements could take a hit. 

The future is simply too murky to put capital at risk. Instead, the smart move is to ignore Alexion and focus, instead, on higher-quality stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.